Patients developing metastatic disease disease free survival. Medical search. Frequent questions

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 3, 2006--Amgen (Nasdaq:AMGN), the world's largest biotechnology company, today announced pivotal Phase 3 results demonstrating that panitumumab significantly improved progression-free survival and disease control (response rate and stable disease) compared to best supportive care (BSC) in metastatic colorectal cancer patients who had failed standard chemotherapy. (amgen.com)
In this multi-national, open-label Phase 3 study, 463 patients with metastatic colorectal cancer who had failed standard chemotherapy, including oxaliplatin and irinotecan, were randomized to receive 6 mg/kg panitumumab plus BSC (n=231) every two weeks or BSC alone (n=232). (amgen.com)
Patients receiving neoadjuvant chemotherapy plus radical nephroureterectomy for upper tract urothelial carcinoma appear more likely to experience nodal downstaging. (cancernetwork.com)
The FDA approved Onivyde in combination with 5-fluorouracil chemotherapy and leucovorin for the treatment of patients with metastatic pancreatic cancer following prior administration of a gemcitabine-based regimen in 2015. (curetoday.com)
The FDA also approved toripalimab , a programmed death receptor 1-blocking antibody, as a single agent for recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or after a platinum-containing chemotherapy. (medscape.com)
The first-line approval was based on the JUPITER-02 trial in 289 patients who had not received previous systemic chemotherapy for recurrent or metastatic disease. (medscape.com)
Efficacy of toripalimab as a single agent was evaluated in the POLARIS-02 study in 172 patients with unresectable or metastatic nasopharyngeal carcinoma who had received prior platinum-based chemotherapy or had progressed within 6 months of its completion in the neoadjuvant, adjuvant, or definitive chemoradiation setting. (medscape.com)
However, in a recent COG report, the authors demonstrated that intensive multimodal therapies-including high-dose chemotherapy, radiation, and bone marrow transplantation-have enabled improved efficacy for curing patients with regional extraocular retinoblastoma (87% event-free survival [EFS] at 36 months) and metastatic retinoblastoma not involving the CNS (79% EFS at 36 months), while rates for patients with CNS disease continue to be dismal (8% EFS at 36 months). (aao.org)
Up to 20% of patients with bilateral retinoblastoma treated with chemotherapy will present with a second nonocular tumor within 20 years, and in up to 40% of those who were irradiated, a second or third nonocular tumor will develop. (aao.org)
In addition, results presented earlier this week at the AACR Annual Meeting 2018 , which were simultaneously published in The New England Journal of Medicine and highlighted on this blog , showed that a combination of ipilimumab and nivolumab significantly improved the overall response rate and median progression-free survival among certain patients with non-small cell lung carcinoma, compared with standard-of-care chemotherapy. (aacr.org)
The approval was based on recently published clinical efficacy and safety data from the Phase 3, randomized, open-label, controlled study (ET743-SAR-3007), which evaluated YONDELIS versus the chemotherapy agent dacarbazine, in patients with unresectable or metastatic LPS or LMS previously treated with an anthracycline and at least one additional chemotherapy regimen. (prnewswire.com)
In the trial, dubbed ALINA, Alecensa was compared with platinum-based chemotherapy in 257 patients with resected ALK-positive NSCLC. (outsourcing-pharma.com)
T-DM1 is indicated for patients who were previously treated with the anti- HER2 therapy trastuzumab ( Herceptin , Genentech) and a taxane chemotherapy. (medscape.com)
The international open-label EMILIA study involved 991 patients with HER2 -positive locally advanced breast cancer or metastatic breast cancer who had previously been treated with trastuzumab and a taxane chemotherapy. (medscape.com)
2 For patients with HR positive, HER2 negative metastatic breast cancer that progresses on or is not suitable for hormone therapy-based regimens, current standard of care is single-agent chemotherapy, which demonstrates diminishing efficacy with each subsequent line of treatment. (biospace.com)
Most patients with HR positive, HER2 negative metastatic breast cancer will inevitably progress on available treatments, including hormonal therapy and standard of care chemotherapy. (biospace.com)
The TROPION-Breast01 trial will evaluate whether datopotamab deruxtecan may be a more effective treatment than chemotherapy for patients with previously treated HR positive, HER2 negative advanced breast cancer previously treated with one to two lines of chemotherapy. (biospace.com)
Purpose: Low-dose metronomic chemotherapy is an emergent treatment schedule in which low doses of cytotoxic agents are given orally continuously, with no or short drug-free intervals. (scirp.org)
Twenty six (65%) patients had the opportunity to receive a classic chemotherapy regimen following metronomic regimen interruption. (scirp.org)
In this context, biomarkers that can identify individuals with a favorable prognosis among ER- negative breast cancer patients, for whom the toxic chemotherapy might be avoidable, are of value in choosing appropriate adjuvant therapy. (biomedcentral.com)
This double-blind RCT compares pembrolizumab (an immune checkpoint inhibitor with an average per treatment cost of $10.5K) combined with one of several chemotherapy options to chemotherapy and placebo in previously untreated metastatic triple-negative breast cancer (TNBC), a setting with high unmet patient need. (stopbreastcancer.org)
NEW YORK, November 13, 2023 - Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. (pfizer.com)
This is the first reported case of prolonged survival of metastatic disease in penile cancer in a patient treated using this chemotherapy regime. (bjuinternational.com)
Patients with metastatic disease (~40%) had a historical median OS of approximately 6 months, although recently substantial progress has been made in chemotherapy options for these patients [ 3 ]. (bmj.com)
In these patients who are poor candidates for resection, a combination of chemotherapy, locoregional therapies like ablation, transarterial chemo and radioembolization, and in very advanced and metastatic disease, external radiation are the available options. (mdpi.com)
Despite significant recent advances in treating lung cancer, there is a large unmet medical need for a targeted therapy for these EGFR mutation-positive NSCLC patients, for whom chemotherapy is still the most common treatment option. (drug-dev.com)
Dosing of the first patients in the BDTX-1535 dose expansion cohorts represents an important step towards offering an oral therapeutic with manageable side effects as a potential alternative to chemotherapy-based regimens following progression on osimertinib for patients with treatment-resistant lung cancer," said David Epstein, PhD, President and Chief Executive Officer of Black Diamond Therapeutics. (drug-dev.com)
as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. (who.int)
Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)

Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients newly diagnosed with advanced renal cell carcinoma, the most common form of kidney cancer . (aacr.org)
One prediction model developed by the International Metastatic Renal-Cell Carcinoma Database Consortium classifies patients based on the presence or absence of six risk factors. (aacr.org)
There are other (or newer) ICIs (such as anti-PD1 and anti-PD-L1 antibodies), considered to be effective therapies in subsets of patients with a variety of tumor types such as metastatic melanoma, non-small cell lung cancer (NSCLC), prostate cancer, renal cell carcinoma, and so on. (patent-art.com)
NK cell infiltration into tumor tissue is associated with better disease prognosis in colorectal cancer, clear cell renal cell carcinoma, and lung carcinomas ( 9 - 11 ). (frontiersin.org)
The development of adjuvant treatment options that not only delay but also prevent recurrent disease remains an unmet need in the treatment of patients with renal cell carcinoma. (ascopost.com)
After we moved into the targeted therapy era in 2005, with vascular endothelial growth factor (VEGF) targeting agents demonstrating efficacy for metastatic renal cell carcinoma, a series of studies were designed to investigate the efficacy of adjuvant VEGF-targeting tyrosine kinase inhibitors. (ascopost.com)
In aggregate, all studies to date were negative, with the exception of the phase III S-TRAC study, which tested the adjuvant use of sunitinib in patients with locally advanced (pT3-4) or node-positive clear cell renal cell carcinoma. (ascopost.com)
The results of the S-TRAC trial contrasted with those of the large phase III ASSURE trial, which tested the efficacy of sunitinib vs sorafenib vs placebo in patients with renal cell carcinoma at high risk of recurrence. (ascopost.com)
The KEYNOTE-564 study is the first positive adjuvant immunotherapy trial in patients with resected renal cell carcinoma and presents an advancement in the care of these patients. (ascopost.com)
Although the ASSURE trial enrolled a heterogeneous patient population, including those with either clear cell or variant histology renal cell carcinoma and either pT1b grade 3-4, pT2-T4, or node-positive disease, subset analyses in patients with clear cell renal cell carcinoma with pT3-4 or node-positive disease failed to demonstrate a benefit with adjuvant sunitinib. (ascopost.com)
Despite these mixed results with sunitinib, in 2017, the U.S. Food and Drug Administration (FDA) granted approval for adjuvant sunitinib in patients with renal cell carcinoma. (ascopost.com)
At the time that approval for adjuvant sunitinib was granted, single-agent immune checkpoint inhibitors had demonstrated efficacy for patients with metastatic renal cell carcinoma and had entered the treatment armamentarium. (ascopost.com)
The first checkpoint inhibitor approved for renal cell carcinoma was nivolumab in 2015, based on the results of the phase III CheckMate 025 study testing the efficacy of nivolumab vs everolimus in patients having received prior VEGF-targeting therapy. (ascopost.com)
The KEYNOTE-564 study was a phase III, double-blind, randomized, placebo-controlled trial testing the efficacy of pembrolizumab vs placebo as adjuvant therapy for patients with clear cell renal cell carcinoma at high risk of recurrence following definitive nephrectomy. (ascopost.com)
7 The study, which was reported in The New England Journal of Medicine by Choueiri et al and is summarized in this issue of The ASCO Post , is the first positive adjuvant immunotherapy trial in patients with resected renal cell carcinoma and represents an advancement in the care of these patients. (ascopost.com)
Patients and Methods Atezolizumab data from clinical trials in non-small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. (medscape.com)

today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC). (takeda.com)
We are confident that fruquintinib has the potential to transform the treatment landscape for those living with previously treated metastatic colorectal cancer, as demonstrated by its strong clinical profile," said Awny Farajallah, M.D., head of Global Medical Affairs Oncology at Takeda. (takeda.com)
In this review we will discuss various treatment options available in management of colorectal liver metastases with potential guidance on how and when to choose these options along with consideration on future directions in management of this disease. (wjgnet.com)
Colorectal liver metastasises were once considered as incurable disease but with better treatment options and valuable input from multi-disciplinary teams, this disease can be cured in a proportion of patients. (wjgnet.com)
In the early stages of the disease, colorectal cancer often causes no symptoms at all, or only vague ones. (lu.se)
The research team at Lund University's Department of Clinical Sciences in Malmö conducts patient-centred research into bowel diseases, eg risk factors for recurrence of colorectal cancer as well as functional results after cancer surgery. (lu.se)
Research has also shown that many people affected by colorectal cancer become acutely ill and then have a much poorer survival prognosis. (lu.se)
PhaRmacogEnomiC medIcines optimiSatIon for peOple with caNcer - a multicentre teletrial enabled Interrupted Time Series trial (PRECISION-ITS): A nested cohort substudy evaluating the safety & efficacy of 5-Fluorouracil Therapeutic Drug Monitoring in patients with metastatic/unresectable colorectal cancer. (who.int)

Children with intraocular retinoblastoma who have access to modern medical care have a very good prognosis for survival (>95% in industrialized countries). (aao.org)
Historically, children with extraocular retinoblastoma had a very poor prognosis for survival. (aao.org)
In this clinical context, the likely prognosis of patients can be predicted depending on the presence of certain risk factors, such as anemia, hypercalcemia, neutrophilia, and thrombocytosis. (aacr.org)
After primary tumor treatment, 30% of patients with malignant melanoma develop metastatic disease, usually associated with a poor prognosis. (unimore.it)
The implication of PTPRK in disease progression and prognosis was analysed which was also further supported by analyses of RNAseq data of pancreatic cancer (The Cancer Genome Atlas, TCGA_PAAD) and a gene array data (GSE15471 and GSE71729). (cardiff.ac.uk)
TDM-1 does not provide a "major change in prognosis" for women with metastatic disease who have progressed on trastuzumab treatment, he wrote, adding that it is likely to be "very expensive. (medscape.com)
MACC1 may represent a potentially useful biomarker for the prognosis of breast cancer patients and might be involved in progression of breast cancer. (biomedcentral.com)
Despite intensive research in recent decades the prognosis for patients with metastatic or relapsed diseases has hardly improved. (frontiersin.org)
The risk of distant recurrence in breast cancer patients is difficult to prognostic indices, such as the Nottingham Prognostic Index (6, 7), assess with current clinical and histopathological parameters, and have proven valuable in identifying patients with poor prognosis. (lu.se)
Although pulmonary carcinoids show relatively good prognosis in comparison to carcinomas, metastatic disease and relapse do occur. (who.int)

Desmoplastic histologic subtype is a strong predictor of brain metastasis development and decreased 2-year BMFS in patients with metastatic melanoma. (cancernetwork.com)
Patients with desmoplastic melanoma, particularly thick lesions involving the H&N, should be imaged frequently during the first year after the diagnosis of stage IV disease. (cancernetwork.com)
Brain metastases are a major cause of mortality in metastatic melanoma. (cancernetwork.com)
A prospective institutional melanoma database was used to identify patients diagnosed with metastatic melanoma between 1971 and 2013. (cancernetwork.com)
Among 3,756 patients with metastatic melanoma, 711 (18.9%) developed brain metastases. (cancernetwork.com)
Of the 25 patients diagnosed with desmoplastic melanoma, 9 (36%) were found to have brain metastases, all within the first year after the diagnosis of another systemic disease. (cancernetwork.com)
As discussed on this blog , they were approved in combination for treating certain patients with metastatic melanoma in September 2015. (aacr.org)
the liver is the first site of metastasis for 80%-90% of ocular melanoma patients. (wikipedia.org)
Effective chemotherapeutic regimens for metastatic melanoma are not currently available. (unimore.it)
In 2011, FDA first approved an immune checkpoint inhibitor (ICI), ipilimumab, a monoclonal antibody targeting CTLA-4, which extended the overall survival rate of patients with metastatic melanoma. (patent-art.com)
Neoantigen cancer vaccines are capable of eliciting strong T cell responses to neoepitopes in patients with melanoma. (patent-art.com)
It must be remembered that a definitive survival benefit of SLNB in melanoma patients has not been proven yet. (hindawi.com)
20 years ago [ 1 ], sentinel lymph node biopsy (SLNB) was introduced for melanoma patients and later for numerous other tumors with lymphatic metastatic propensity. (hindawi.com)
Even though surgical oncology community is divided in believers and nonbelievers regarding its application, data show that SLNB has already changed the treatments modalities in melanoma and breast cancer patients, at least with respect to TNM classification. (hindawi.com)
The patients were identified and registered in parallel of a melanoma patients' registry (550 SLNB during the same time), and a retrospective analysis was performed. (hindawi.com)
This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease. (cancernetwork.com)
Melanoma is a disease that demonstrates a wide range of clinical behavior from relatively indolent to aggressive metastatic disease. (lu.se)
Today, the combination of BRAF and MEK inhibitors are becoming the routine treatment of choice in metastatic melanoma. (lu.se)
Previously, we have established that melanoma can be grouped in gene expression phenotypes with immune-rich melanomas having improved patient survival. (lu.se)
Ultimately, our results will improve our understanding of the complexity of melanoma biology as well as having an impact in the clinical setting as such information can be used to develop prognostic and predictive molecular signatures. (lu.se)
Immune-related response criteria (irRC) were developed based on experience with ipilimumab (anti-cytotoxic T-cell lymphocyte-4) in melanoma to better capture the response to CIT per changes in tumor biology and the long-termeffects of CITon solid tumors and to enable additional adaptations as the field evolved. (medscape.com)

The objective response rate (measuring how much tumors shrink from treatment) for patients treated with NALIRIFOX was 41.8% and was 36.2% for those treated with nab-paclitaxel and gemcitabine, according to the news release. (curetoday.com)
Developed as the next generation of immunotherapy, it uses personal and precision vaccines as well as T cell therapies to direct T cells directly toward a patient's tumors. (patent-art.com)
Neoantigen vaccines and immune checkpoint inhibition act as complementary treatments that might often be used together, especially for patients with large tumors or metastatic disease, and can lead to an increased tumor-specific immune response. (patent-art.com)
However, as tumors progress, cancerous cells develop immunosuppressive mechanisms that circumvent NK cell-mediated killing, allowing for tumor escape and proliferation. (frontiersin.org)
Although these tumors develop most often in the pancreas, they may appear in other organs, particularly the duodenum, jejunum, and lung. (msdmanuals.com)
Overview of Multiple Endocrine Neoplasias (MEN) The multiple endocrine neoplasia (MEN) syndromes comprise 4 genetically distinct familial diseases involving adenomatous hyperplasia and malignant tumors in several endocrine glands. (msdmanuals.com)
Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). (msdmanuals.com)
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. (medscape.com)
Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 end points, originally developed to evaluate the benefit of chemotherapeutic and targeted agents, are accepted measures of clinical efficacy in advanced solid malignancies. (medscape.com)
Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers. (medlineplus.gov)

On May 4, 2022 , fam-trastuzumab deruxtecan-nxki (T-DXd) was granted regular approval for patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. (ascopost.com)

Panitumumab treatment also showed a clinical benefit in the patients crossing over from the BSC arm, despite their disease progression. (amgen.com)
Patients and physicians can access www.amgentrials.com for more information about ongoing panitumumab clinical trials. (amgen.com)
In patients considering clinical trial enrollment, the risks and potential benefits of experimental treatment modalities must be clearly outlined. (medscape.com)
Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care. (cancernetwork.com)
To report clinical outcomes in terms of disease control and toxicity in patients with major salivary gland cancers (SGCs) treated with proton beam therapy. (allenpress.com)
Clinical and dosimetric characteristics of patients with SGCs treated from August 2011 to February 2020 on an observational, prospective, single-institution protocol were abstracted. (allenpress.com)
The NALIRIFOX regimen of Onivyde plus 5-fluorouracil/leucovorin and oxaliplatin has been shown to have survival and disease progression benefits for patients with pancreatic cancer in a clinical trial setting. (curetoday.com)
An open-label, randomized clinical trial, NAPOLI 3, according to its listing on clinicaltrials.gov, began in February 2020 and had the participation of 770 patients ages 18 and older with histological or cytologically confirmed adenocarcinoma of the pancreas that had not been previously treated in the metastatic setting. (curetoday.com)
Patients in the NALIRIFOX group had a median overall survival of 11.1 months, while those in the nab-paclitaxel and gemcitabine group had a median overall survival of 9.2 months, according to data from Ipsen originally presented at the January 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. (curetoday.com)
In 2013, after patients in a clinical study led by UCLA researchers showed a dramatic improvement, the FDA granted the drug "breakthrough therapy" status, allowing it to be fast-tracked for approval. (uclahealth.org)
TDM-1 does not meet [the] goals of a major advance," wrote Dr. Vogl, who explained that such an advance must cure some patients, increase the rate of clinical complete remission, or produce a high rate of very long partial response. (medscape.com)
Because of the low incidence of nonmelanoma skin cancer with potential metastatic spread and the lack of large clinical trials, the use of SLNB in these cases is not well established, and no guidelines are currently available. (hindawi.com)
Statistical analysis showed a significant correlation of MACC1 expression with the primary tumor, lymph node metastasis, distant metastasis classifications as well as the clinical staging in breast cancer patients. (biomedcentral.com)
Breast cancer is a heterogeneous disease with a variety of different molecular subtypes and varied clinical outcomes. (biomedcentral.com)
Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer. (cancernetwork.com)
HOUSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, "the Company"), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment. (aravive.com)
We want to thank the patients who participated in this trial, the clinical investigators, and the Aravive team for their hard work, as we continue to pursue our goal of finding innovative cancer treatments for patients in need. (aravive.com)
Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. (aravive.com)
While factors influencing outcomes of rhabdomyosarcoma (RMS) in developed countries have evolved from clinical characteristics to molecular profiles, similar data from developing countries are scarce. (ecancer.org)
People with metastases in the liver in particular do very poorly, and in some clinical trials those patients were actually excluded from being tested. (onclive.com)
The future design of clinical trials in prostate cancer will learn a lot from current studies that are studying metastasis-free survival and are exploring the nature of therapies in the nonmetastatic castration-resistant patient population. (onclive.com)
However, in clinical practice, utilization of sunitinib remains limited, given no appreciable benefit in overall survival and increased toxicity. (ascopost.com)
Black Diamond Therapeutics, Inc. recently announced the first patients dosed in mutation matched expansion cohorts of non-small cell lung cancer (NSCLC) in the ongoing Phase 1 clinical study evaluating BDTX-1535. (drug-dev.com)
The dosing of the first patients in the expansion cohorts follows the company's initial data readout from the dose escalation portion of the BDTX-1535 Phase 1 clinical study, which demonstrated clinical proof of activity through radiographic responses in NSCLC patients harboring diverse types of EGFR mutations including intrinsic driver and post-osimertinib acquired resistance EGFR mutations. (drug-dev.com)
Thirteen percent of patients in the US with EGFR mutation-positive NSCLC show presence of intrinsic driver mutations, which are associated with worse clinical outcomes when treated with currently approved EGFR TKIs. (drug-dev.com)
To avoid these confounding factors, we focused on a more homogeneous population of patients with MSSA catheter-related bloodstream infection (MSSA CRBSI) for whom specific efforts were devoted to optimize clinical management. (cdc.gov)
Hydroxyurea has proven clinical efficacy for SCA - treatment significantly reduces disease manifestations and prolongs survival. (cdc.gov)
This review describes current considerations in the use of hydroxyurea for the management of sickle cell disease in the context of clinical severity. (cdc.gov)
3. Patients receiving a pharmacogenomics drug of interest (Appendix 1) as an investigational medicinal product in another interventional clinical drug trial that prohibits concurrent enrolment (as part of eligibility or PI's discretion), or that represents an unreasonable burden of patient participation at the discretion of the patient or investigator. (who.int)
It is the decision of the clinician to implement/not implement dose changes after considering both exposure levels and other clinical factors such as observed toxicities and treatment intent/patient goals of care. (who.int)
ABSTRACT The study's objective was to evaluate the clinical significance of sCD40L in HCV- associated hepatocellular carcinoma (HCV-HCC) patients. (who.int)

The U.S. Food and Drug Administration today approved a new drug to treat patients with advanced breast cancer, signaling a new strategy for arresting tumor growth and extending the time before cancer worsens in women with metastatic disease. (uclahealth.org)

A phage display reveals prognostic proteins in prostate cancer patients. (the-scientist.com)
In the December 23 Nature Biotechnology , Paul Mintz and colleagues at The University of Texas M.D. Anderson Cancer Center , Houston, USA, show that phage-display systems can also be used to uncover and validate a specific prognostic serological marker derived from prostate cancer patients ( Nature Biotechnology , doi10.1038/nbt774, December 23, 2002). (the-scientist.com)
As seen in BRAF, mutations in GNAQ/GNA11 are early events in tumorigenesis and are not prognostic for tumor stage or later metastatic spread. (wikipedia.org)
Stratification of breast cancer patients according to the estrogen receptor (ER) status revealed that MACC1 was prognostic for both ER-negative and ER-positive patients. (biomedcentral.com)
This is a single-centre analysis of outcomes in treated cases of RMS, with emphasis on prevalence, risk-migration and prognostic impact of Forkhead Box O1 ( FOXO1) in non-metastatic RMS. (ecancer.org)
The International Germ Cell Cancer Consensus Group (IGCCCG) developed a risk classification for advanced nonseminoma testicular cancer based on identifying clinically independent prognostic features, including extent of disease and levels of serum tumor markers. (medscape.com)
The risk of developing distant strated enough prognostic accuracy in breast cancer (10). (lu.se)
We investigated the prognostic role of high MICs for antistaphylococcal agents in patients with methicillin-sensitive Staphylococcus aureus catheter-related bloodstream infection (MSSA CRBSI). (cdc.gov)
We designed this multicenter prospective study to confirm the prognostic role of high MICs for vancomycin and to explore if increased MICs for other antistaphylococcal agents could also influence the risk for developing complicated MSSA CRBSI. (cdc.gov)

After study findings showed that patients in the NALIRIFOX group had a median overall survival of 11.1 months, while those in the nab-paclitaxel and gemcitabine group had a median overall survival of 9.2 months, the FDA agreed to review the regimen for metastatic pancreatic cancer treatment. (curetoday.com)
In addition, at that time, it was not possible to estimate the median overall survival among those receiving the immunotherapy combination, whereas it was estimated to be 25.9 months among those who received sunitinib. (aacr.org)
In the pivotal phase 3 EMILIA study, patients receiving T-DM1 survived nearly 6 months longer than patients receiving the standard therapy of lapatinib ( Tykerb ) plus capecitabine ( Xeloda ) (median overall survival, 30.9 vs 25.1 months). (medscape.com)
Although patient survival for breast cancer has been improved in recent decades[ 9 ], the outcome of patients with metastatic breast cancer remains poor with a median overall survival time of 2 to 3 years[ 10 ]. (biomedcentral.com)
Long-awaited overall survival data from another trial, KEYNOTE 355 were also presented at ESMO 2021 and showed that median overall survival was improved by nearly 7 months with pembrolizumab (23.0 months) compared to chemo and placebo (16.1 months). (stopbreastcancer.org)
In those with locally advanced or unresectable disease (~30%-40% of patients) the median overall survival (OS) has been between 8 and 14 months. (bmj.com)

The US Food and Drug Administration (FDA) has approved toripalimab-tpzi (Loqtorz, Coherus BioSciences) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. (medscape.com)
METHODS AND MATERIALS: Data from 101 patients treated at our institution for locally recurrent PCa from June 2012 to June 2021 were retrospectively collected. (bvsalud.org)
CONCLUSIONS: After almost 5 years of follow-up, with a median BRFS of 40.4 months and no grade ≥ 2 AEs, CyberknifeR rSBRT proved effective and safe in a cohort of 101 patients affected by locally recurrent PCa. (bvsalud.org)
Although many patients who present with localized disease are cured with definitive surgery, some patients develop distant recurrent disease. (ascopost.com)
The trial is evaluating BDTX-1535 in patients with advanced/metastatic NSCLC harboring EGFR mutations with or without central nervous system (CNS) disease, or with recurrent GBM expressing EGFR alterations. (drug-dev.com)
Treatment protocols for nonseminoma testicular cancer are provided below, including recommendations for treatment of stage I-III disease, second-line recommendations for metastatic disease, and recommendations for persistent or recurrent disease. (medscape.com)

Our academic teams are dedicated to finding new treatments with scientific merit and the promise to improve outcomes for patients with sarcomas. (prnewswire.com)
Given the limited evidence supporting these endorsements, we examined outcomes for 152 patients who underwent surgery for well-differentiated thyroid carcinoma at Memorial Sloan Kettering Cancer Center (MSK) from 1986 to 2015. (mskcc.org)
Alecensa has transformed outcomes for people with advanced ALK-positive NSCLC, and now these strong results provide evidence for the first time that this medicine could also play a pivotal role in early-stage disease where there is significant unmet need," said Roche's chief medical officer and head of global product development, Levi Garraway, in a public statement. (outsourcing-pharma.com)
Secondary endpoints include PFS assessed by investigator, objective response rate, duration of response, disease control rate, and patient reported outcomes, as well as safety and pharmacokinetics. (biospace.com)
Is it well designed, blinded, and powered to measure clinically meaningful outcomes (i.e., overall survival and/or quality of life)? (stopbreastcancer.org)
Minimally invasive biomarkers predictive of cediranib benefit may improve patient outcomes. (nature.com)
And I think this is a really good example where an earlier intervention by preventing a complication may actually lead to an improvement in the overall outcomes of a substantial margin of patients with this disease. (onclive.com)
This guidance is intended to help clinicians in outpatient settings test for these fungal diseases in patients with CAP to reduce misdiagnoses, unnecessary antibacterial use, and poor outcomes. (cdc.gov)

In the trial, 524 patients who had received prior trastuzumab and taxane therapy for metastatic disease or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy were randomly assigned to receive trastuzumab deruxtecan at 5.4 mg/kg (n = 261) or ado-trastuzumab emtansine (T-DM1) at 3.6 mg/kg (n = 263) every 3 weeks until unacceptable toxicity or disease progression. (ascopost.com)
The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial. (outsourcing-pharma.com)
Roche is aiming to develop the drug in earlier stages of the disease as an adjuvant therapy following surgical removal of the tumor. (outsourcing-pharma.com)
Historically, trials of adjuvant cytokine-based treatments have failed to demonstrate improvements in disease-free survival for patients at high risk of recurrence following definitive surgical resection. (ascopost.com)
3 The study demonstrated an improvement in disease-free survival (6.2 months vs 4.0 months, hazard ratio [HR] = 0.74, 95% confidence interval [CI] = 0.55-0.99, P = .04) with adjuvant sunitinib over placebo, with no benefit in overall survival (HR = 0.92, 95% CI = 0.66-1.28) and increased toxicity. (ascopost.com)
analyzing the velocity (i.e., the change over time) of the markers, malignancy we could stipulate for each patient the risk of developing metas- tasis after the end of adjuvant systemic therapy. (lu.se)

While advanced prostate cancer was historically defined as distant metastatic disease, the current definition includes disease stages that range from recurrence of prostate-specific antigen (PSA) elevation after failure of local treatment to widespread metastasis. (medscape.com)
High-grade prostate cancer, particularly the percentage presence of Gleason grades 4 and 5, is associated with adverse pathologic findings and disease progression. (medscape.com)
Although cure of metastatic prostate cancer remains elusive, continuous advances in management have improved the outlook in these patients. (medscape.com)
For patient education information, see Prostate Cancer . (medscape.com)
The increase in metastatic prostate cancer was greatest (92%) in men aged 55-69 years. (medscape.com)
The 5-year relative survival rate for localized and regional prostate cancer is 100%, compared with 34.1% for metastatic cases. (medscape.com)
[ 5 ] Prostate cancer tends to not only be more aggressive and progressive in Black men, leading to advanced disease, but to also be of a higher grade at diagnosis. (medscape.com)
However, a clear segment of Metastatic Cancer Therapy Market has emerged in last few years with the arrival of products like Provenge which is vaccine specifically indicated for metastatic Prostate cancer. (medgadget.com)
Metastatic cancer therapy market is further segmented into each type of metastatic cancer such as lung cancer, breast cancer, prostate cancer, brain tumor and several others which are the most common types of cancers globally indicating a large target patient base of this segment of the market. (medgadget.com)
Historically, systemic therapy for metastatic and advanced prostate cancer has involved androgen suppression. (medscape.com)
Because a high-fat diet is linked with a higher incidence of prostate cancer, a low-fat diet may be beneficial for patients at high risk of developing prostate cancer (namely those with a positive family history and black men) and patients undergoing treatment of advanced prostate cancer. (medscape.com)
developed a screening method based on phage-display random-peptide libraries and identified a consensus motif - NXS/TDKS/T - that bound selectively to circulating antibodies from patients with prostate cancer. (the-scientist.com)
PURPOSE: Up to 47% of patients with localized prostate cancer (PCa) treated with radiotherapy (EBRT) eventually develop local recurrence. (bvsalud.org)
Patients underwent rSBRT with CyberKnife system (Accuray Inc., Sunnyvale, CA, USA), delivered to intraprostatic or macroscopic recurrences within the prostate bed, for a total dose of 30 Gy in 5 fractions. (bvsalud.org)
Continuous advances have provided a new understanding of the diagnosis, staging, and treatment of metastatic and advanced prostate cancer. (medscape.com)
Most prostate cancer-related deaths are due to advanced disease, which results from any combination of lymphatic, blood, or contiguous local spread. (medscape.com)
For patient education information, see the Men's Health Center and the Cancer Center, as well as Prostate Cancer. (medscape.com)
An estimated 1 in 10 men will develop prostate cancer in their lifetime, with the likelihood increasing with age. (medscape.com)
Despite the apparent survival advantage of early diagnosis conferred by PSA screening, a 2008 US Preventive Services Task Force statement recommended against screening for prostate cancer in men aged 75 years or older. (medscape.com)
Why is it that a patient will have prostate cancer and live seemingly forever, or for his entire natural life, without developing metastasis, and the next gentleman who starts at about the same point develops metastases in a couple of years? (onclive.com)
As I think about the treatment of patients with prostate cancer, I have 3 goals that I summarize with the expression, "the 3 Ps. (onclive.com)
Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race . (owiki.org)
Most men with prostate cancer do not end up dying from the disease. (owiki.org)
A study based on the 1998 Patient Care Evaluation in the US found that about a third of patients diagnosed with prostate cancer had one or more such symptoms, while two-thirds had no symptoms. (owiki.org)
Metastatic prostate cancer that has spread to other parts of the body can cause additional symptoms. (owiki.org)
Targeting the androgen receptor (AR) pathway prolongs survival in patients with prostate cancer, but resistance rapidly develops. (lu.se)
AR-regulated human kallikrein-related peptidase 2 (free hK2) is a prostate tissue-specific antigen produced in prostate cancer and androgen-stimulated breast cancer cells. (lu.se)
The patient survives, but because the tumour has grown over other organs in the pelvis, it is necessary to remove the bladder, prostate or uterus. (lu.se)
Author Manuscript treatment choice facing prostate cancer patients. (cdc.gov)

The recommended dose as a single agent for previously treated nasopharyngeal carcinoma is 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity. (medscape.com)
If approved, fruquintinib will be the first and only highly selective inhibitor of all three VEGF receptors approved in the U.S. for previously treated metastatic CRC. (takeda.com)
The trial did not show any difference between the two arms in the overall population (which included patients previously treated with bevacizumab). (aravive.com)
Methods Patients with a PS 0-1, HLA-A2+ and CEA-expressing, previously-treated PC were randomized to receive 10 μg (arm A), 100 μg (arm B) or 1000 μg (arm C) of CEA peptide emulsified in Montanide and GM-CSF, given every 2 weeks until disease progression. (bmj.com)

Moreover, PTPRK is down regulated in distant metastatic tumours from pancreatic cancer (GSE71729). (cardiff.ac.uk)

Primary endpoints were development of brain metastases and 2-year brain metastases-free survival (BMFS). (cancernetwork.com)
Histology was available for 2,132 patients, 397 (18.6%) of whom developed brain metastases (32 [8.1%] brain only, 38 [9.6%] brain as the first site of stage IV disease). (cancernetwork.com)
Prospective pilot study to assess patient outcome after stereotactic body radiation therapy (SBRT) for limited metastases from breast cancer. (nih.gov)
SBRT may yield prolonged survival and perhaps cure in select patients with limited metastases. (nih.gov)
Approximately 50 percent of patients will develop metastases within 15 years after treatment of the primary tumor, and the liver will be involved 90% of the time. (wikipedia.org)
Surgical treatment of pulmonary metastases remains controversial because of the dismal survival rates reported in several studies. (unimore.it)
There is no significant change of PTPRK expression in the primary tumours that developed distant metastases. (cardiff.ac.uk)
And so, the endpoint of treating that condition is when the patient develops metastases. (onclive.com)
The whole rationale behind these trials with apalutamide and enzalutamide and darolutamide are to use them in these men who have M0 CRPC to see if we can significantly extend the time until that patient has metastases. (onclive.com)
When one looks at metastasis-free survival, we're looking at the prevention of metastases and how that might correlate with overall survival. (onclive.com)

It is recommended that patients with germline RB1 mutations adhere to lifelong risk-modification practices, such as not smoking, avoiding unnecessary radiation exposure, and applying sunscreen. (aao.org)
Although it may be feasible to conduct annual whole-body MRI procedures on patients with RB1 germline mutations beginning at age 8-10 years (when general anesthesia would no longer be required), there is no consensus on the use of whole-body imaging as a surveillance tool. (aao.org)
In contrast, mutations in the gene BAP1 are strongly linked to metastatic spread and patient survival. (wikipedia.org)
The genome sequencing of cancer cells has identified heterogeneity and tens to thousands of somatic mutations that vary among individual patients. (patent-art.com)
The indication CHMP recommended is applicable to all patients, with or without gene mutations. (pfizer.com)
The BDTX-1535 expansion cohort portion of the study will assess single-agent objective response rate (ORR) in a second- or third-line setting in NSCLC patients with EGFR intrinsic driver and/or acquired resistance mutations, who have received prior treatment with approved EGFR TKI. (drug-dev.com)
The Phase 1 expansion cohorts will assess objective response rate and durability of response in NSCLC patients whose disease has progressed after prior EGFR inhibitor therapy, including prior osimertinib, and who have evidence of a variety of EGFR driver or resistance mutations that are targeted by BDTX-1535," said Sergey Yurasov, MD, PhD, Chief Medical Officer of Black Diamond Therapeutics. (drug-dev.com)
BDTX-1535 was designed to disrupt the limited existing treatment paradigm by addressing real-world patterns of patient-specific EGFR mutations, and we remain focused on the rapid advancement of this novel MasterKey inhibitor. (drug-dev.com)
The discovery and development of BDTX-1535 was informed by the company's powerful Mutation-Allostery-Pharmacology (MAP) drug discovery engine, which leverages critical genomic profiling to expand the addressable patient population by targeting families of mutations with a single drug. (drug-dev.com)
Emergence of intrinsic driver and acquired resistance EGFR mutations to osimertinib represents a significant unmet need for patients with EGFR-mutant lung cancer. (drug-dev.com)
Fifteen percent of patients in the US whose disease has progressed after osimertinib therapy show evidence of acquired resistance EGFR mutations (eg, C797S) for which currently there is no approved EGFR TKI. (drug-dev.com)
The company is advancing BDTX-1535 as a potential targeted therapy option for patients with this broad spectrum of EGFR mutations in second-line NSCLC, and plans to investigate safety and efficacy in a first-line setting in NSCLC patients with intrinsic driver EGFR mutations after discussion with the US FDA. (drug-dev.com)

Whilst uncommon in the developed world, biliary tract cancer (BTC including cholangiocarcinoma [CCA], gallbladder and ampullary carcinoma) represent a significant global problem due to areas of high incidence, for instance of liver fluke-associated cholangiocarcinoma in Northern Thailand 1 and of gallbladder cancer in Chile and India. (nature.com)

The drug, Ibrance (palbociclib), was studied in 165 post-menopausal women with advanced estrogen-receptor positive (ER+) and HER2-negative (HER2-) breast cancer who had received no prior systemic therapy for their metastatic disease. (uclahealth.org)
A multiyear phase 2 study found a significantly higher progression-free survival rate for patients with advanced ER+/HER2- breast cancer who were given palbociclib in addition to letrozole, a standard anti-estrogen treatment, compared with women who received letrozole alone. (uclahealth.org)
I believe palbociclib will now become a standard treatment approach for postmenopausal women with ER+/HER2- metastatic breast cancer. (uclahealth.org)
A phase 2 study evaluated the drug in 165 post-menopausal women with advanced ER+/HER2- breast cancer who had not received prior systemic therapy for their metastatic disease. (uclahealth.org)
The US Food and Drug Administration (FDA) today approved ado-trastuzumab emtansine ( Kadcyla , Genentech), also known as T-DM1, for the treatment of patients with HER2 -positive metastatic breast cancer. (medscape.com)
Apart from lapatinib, which is marketed by GlaxoSmithKline, all the other HER2 -targeted products have been developed and are marketed by Genentech/Roche. (medscape.com)
Our HER2 -positive patients with metastatic disease have another very powerful therapy that offers the real hope for prolonged disease control with less toxicity," she said. (medscape.com)

Currently, the only possibility of cure is through surgical resection, but only approximately 15%-20% of patients are eligible candidates at diagnosis and even with surgery the 5-year overall survival in multiple series is 10%-30% [ 2 ]. (bmj.com)
If diagnosed early these can be resected, but most cases of intrahepatic cholangiocarcinoma present late in the disease course where surgical resection is not an option. (mdpi.com)

Such conditions are termed as metastatic cancers. (medgadget.com)
In 2017, 600920 deaths occurred due to metastatic cancers in US alone. (medgadget.com)
In developing countries, the death rates due to metastatic cancers are even higher due to lack of early stage diagnosis of cancer. (medgadget.com)
Earlier, lesser therapies were available for increasing the period of progression free survival of patients with metastatic cancers and the metastatic cancer market was not clearly differentiated from overall cancer therapy market. (medgadget.com)
High medical needs of patients with metastatic cancers have fuelled global metastatic cancer therapy market at an impressive average 8 CAGR calculated on the basis of the market growth for each indication. (medgadget.com)
These studies revealed that MACC1 might play a role in the recurrence, metastasis and patient survival in various types of human cancers. (biomedcentral.com)
Humanized 11B6, which has undergone toxicological tests in nonhuman primates, has the potential to improve patient management in these cancers. (lu.se)
Hereditary ovarian cancers tend to develop earlier in life than non-inherited (sporadic) cases. (medlineplus.gov)

Thirty-two patients (31.7%) developed metastatic disease, with a median metastasis-free survival (MFS) not reached. (bvsalud.org)
The good news is that the studies that have been done by looking at several thousand patients, I think over 100 studies, demonstrate that metastasis-free survival is highly correlated with overall survival with a correlation coefficient of about 0.9, meaning that they're very, very tightly linked. (onclive.com)
And so, if we took a population where we were to improve their metastasis-free survival and a population where we didn't, we would expect that those who had the improvement in the metastasis-free survival would also enjoy a longer overall survival. (onclive.com)

In these patients, panitumumab treatment resulted in a nine percent partial response and 32 percent stable disease, as well as one complete response. (amgen.com)
The rate (75 percent) and timing (median 7.0 weeks) of crossover from the BSC alone arm to receiving panitumumab, and the anti-tumor activity observed after crossover, likely confounded the ability to demonstrate a treatment effect on overall survival (Hazard ratio = 0.93). (amgen.com)
More than half of the patients with non-muscle-invasive bladder cancer in the BOND-003 trial achieve a complete response at 6 months following treatment with cretostimogene grenadenorepvec. (cancernetwork.com)
The Food and Drug Administration (FDA) accepted a supplemental new drug application for Onivyde (irinotecan liposome injection) plus 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a potential first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma, according to a press release from biopharmaceutical company, Ipsen. (curetoday.com)
The review follows the results from the phase 3 NAPOLI trial, comparing overall survival (the time from treatment until death of any cause) and progression-free survival (the time during and after treatment a patient lives without the disease worsening) of patients treated with Onivyde, administered twice in a month, versus those treated with nab-paclitaxel plus gemcitabine three times in a month. (curetoday.com)
Pancreatic ductal adenocarcinoma) is a devastating disease in need of additional treatment options. (curetoday.com)
The FDA's decision to accept the sNDA for this Onivyde-based regimen in treatment-naïve patients with metastatic disease represents an important milestone in the potential treatment of this complex form of cancer," Howard Mayer, executive vice president and head of research and development at Ipsen, said in the news release. (curetoday.com)
If I cannot, my focus is to lead patients and their families through the treatment process, with an emphasis on providing clear, straightforward communication. (stanfordchildrens.org)
Over 80 percent of the women in the study with metastatic ER+ breast cancer received some benefit from the treatment. (uclahealth.org)
Oct. 23, 2015 /PRNewswire/ -- Janssen Biotech, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved YONDELIS ® (trabectedin) for the treatment of patients with unresectable (unable to be removed with surgery) or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen. (prnewswire.com)
We are proud that our Phase 3 study is the largest ever conducted in this patient population and we're delighted that patients in the U.S. can now benefit from the treatment. (prnewswire.com)
Metastasis can occur more than 10 years after treatment of the primary tumor, and patients should not be considered cured even after a 10-year interval of monitoring. (wikipedia.org)
Product labeling provides instructions on dosage modification, including dose reduction and interruption and discontinuation of treatment, for adverse reactions including interstitial lung disease/pneumonitis, neutropenia, febrile neutropenia, thrombocytopenia, and left-ventricular dysfunction. (ascopost.com)
The drug is already approved by the U.S. Food and Drug Administration (FDA) as a first-line treatment for ALK-positive, metastatic NSCLC. (outsourcing-pharma.com)
On the other hand, in order to provide our patients with the opportunity of receiving many treatment lines with sustained or improved quality of life, we must be able to develop better supportive measure strategies as well as less toxic treatments. (scirp.org)
Historically, most cytotoxic treatment regimens have been developed to be used at its maximum tolerated dose (MTD), in order to achieve better tumor control. (scirp.org)
It has allowed a better understanding of disease progression and response to treatment in patients with comparable staging groups. (hindawi.com)
The next leap forward in breast cancer is identifying patients who would best benefit from a treatment de-escalation approach through the use of precision medicine. (cancernetwork.com)
While providing additional options to men and women with metastatic breast cancer who face limited "good" treatment options, both drugs come with toxicities. (stopbreastcancer.org)
Individuals with metastatic breast cancer go from one treatment to the next and it is important that these treatments are tolerable and used in the right patients, at the right time. (stopbreastcancer.org)
In summary, this two-phased feeder cell-free ex vivo culturing protocol combined efficient expansion and high cytolytic functionality of NK cells for treatment of radiation-resistant RMS. (frontiersin.org)
These studies provide critical insight for moving forward to develop our ASOs for the treatment of cancer patients. (izb-online.de)
ICIs have transformed the treatment of cancer, producing responses in patients with various types of metastatic disease. (izb-online.de)
However, many patients either don't respond or develop resistance to treatment, with only a minority of them showing a durable response. (izb-online.de)
Treatment with IM-T9P1 resulted in the sustained activation of a specific type of tumor infiltrating cell, dendritic cells 3 (DC3s), which can promote antitumor immunity by supporting T cells with survival signals and enabling them to perform their effector functions. (izb-online.de)
Therefore, these studies serve as a roadmap for translation to the human situation for treatment of cancer patients. (izb-online.de)
And although there have been advancements in systemic treatment strategies for patients with advanced disease, the 5-year overall survival for patients with advanced disease is less than 50% in the modern era. (ascopost.com)
In addition to targeted therapies a second generation of immune therapies has been developed with anti-PD1/PDL1 as the main choice of treatment. (lu.se)
Here at Skåne University Hospital in Malmö, we are very interested in these patients whose treatment is centralised here from Southern Sweden, to perform longterm follow up and study complications and survival rates", explains Lydrup. (lu.se)
prior treatment for early stage disease permitted. (who.int)
5. Patient is receiving HIPEC (due to differences in treatment pathways and routine follow-up schedules). (who.int)
We present a simple graphical framework to illustrate the potential welfare gains from a "top-up" health insurance policy requiring patients to pay the incremental price for more expensive treatment options. (cdc.gov)
A natural economic solution which has not received as much attention is a "top-up" design in which health insurance contracts would cover the cost of a baseline treatment, and patients could choose to pay the incremental cost of more expensive treatments out of pocket. (cdc.gov)
By making patients internalize treatment costs on the margin, such a top-up design would result in more efficient sorting of patients across treatments. (cdc.gov)

In a press release , Coherus CEO Denny Lanfear said that the company is "particularly excited to now turn our attention to developing Loqtorzi across multiple tumor types in combination with [immuno-oncology] agents that target the tumor microenvironment," including other agents the company is developing. (medscape.com)
Metastasis-associated in colon cancer-1 (MACC1) was first identified as a transcriptional activator for proto-oncogene c-MET expression, and its overexpression is frequently associated with metastatic progression for multiply tumor types. (biomedcentral.com)

Select patients with papillary thyroid carcinoma with clinically involved lateral neck nodes (cN1b disease) may not require prophylactic central compartment neck dissection (PCND), according to our retrospective study published recently in the Annals of Surgical Oncology . (mskcc.org)
Nonmelanoma skin cancer with potential metastatic spreading to regional lymph nodes regroups skin lesions like high-risk squamous cell carcinoma (SCC), Merkel cell carcinoma (MCC), and pigmented epithelioid melanocytoma (PEM). (hindawi.com)

Patients who received panitumumab every two weeks showed a 46 percent decrease in tumor progression rate versus those who received best supportive care alone (p less than 0.000 000 001). (amgen.com)
For example, after six months (week 24) approximately four times as many panitumumab-treated patients were alive and progression-free (18 percent versus five percent with BSC alone). (amgen.com)
Twice as many panitumumab-treated patients were alive and progression-free at week 32 (10 percent versus four percent with BSC alone). (amgen.com)
Study investigators also reported that panitumumab significantly improved disease control versus BSC alone (36 percent versus 10 percent, respectively), as measured by response rate and stable disease. (amgen.com)
The stable disease rate was 28 percent with panitumumab versus 10 percent with BSC alone. (amgen.com)
Improvements in progression-free survival and disease control also occurred regardless of age, sex, primary tumor location (colon versus rectum), or performance status. (amgen.com)
Currently, predicting whether these patients may benefit from androgen withdrawal versus continued hormone therapy is not possible. (medscape.com)
On univariate analyses, 1 metastatic lesion (versus 2-5), smaller tumor volume, bone-only disease, and stable or regressing lesions prior to SBRT were associated with more favorable outcome. (nih.gov)
Modifications to imRECIST versus RECIST v1.1 included allowance for best overall response after progressive disease (PD) and changes in PD definitions per new lesions (NLs) and nontarget lesions. (medscape.com)
OS was evaluated using conditional landmarks in patients whose PFS differed by imRECIST versus RECIST v1.1. (medscape.com)
Results The best overall response was 1% to 2% greater, the disease control rate was 8% to 13% greater, and the median PFS was 0.5 to 1.5 months longer per imRECIST versus RECIST v1.1. (medscape.com)
The results from this prevali- the field of cancer biomarkers (11-13), and that approach was dation study showed that patients could be classified into high- adopted here to define predictive serum biomarkers associated versus low-risk groups for developing metastatic breast cancer with tumor relapse in breast cancer patients. (lu.se)

A few years later, doctors discovered that the breast cancer had returned as metastatic disease in her bones. (uclahealth.org)
1 Approximately 5% to 10% of women diagnosed with breast cancer have metastatic disease at diagnosis, and up to 30% of women with early-stage breast cancer will develop metastatic disease. (biospace.com)
Is Sentinel Node Biopsy Necessary for Older Breast Cancer Patients? (medpagetoday.com)
It is well known that all these low-dose schedules have a favorable safety profile and may provide an adequate tumor control in patients with metastatic breast cancer. (scirp.org)
Methods: We retrospectively analyzed 40 patients with metastatic breast cancer treated with low doses of Cyclophosphamide and/or Methotrexate and/or Capecitabine in a single center from June 2009 to April 2014. (scirp.org)
In the present study, we analyzed for the first time the expression of MACC1 in breast cancer and its correlation with clinicopathologic features, including metastasis and patient survival. (biomedcentral.com)
The poor outcome of metastatic breast cancer patients underscores the importance of defining molecular factors responsible for cancer metastasis. (biomedcentral.com)
Therefore, identifying risk markers to elucidate pathways responsible for breast cancer metastasis is important for the improvement of the risk classification in patients as well as discovery of therapeutic targets. (biomedcentral.com)
The biggest news coming out of ESMO 2021, largely described as "practice-changing," were the early results of DESTINY-Breast03 , which is an ongoing head-to-head randomized controlled trial (RCT) comparing Enhertu (trastuzumab deruxtecan) with Kadcycla (trastuzumab emtansine [T-DM1])[1] in the second-line setting of HER2+ unresectable and/or metastatic breast cancer. (stopbreastcancer.org)
Approximately 10% of patients treated with Enhertu developed ILD in the single-arm trial that led to the accelerated approval of this drug in the third-line setting of HER2+ metastatic breast cancer. (stopbreastcancer.org)
However, a simple way to screened 240 sera from 64 patients with primary breast cancer. (lu.se)
The samples were collected from breast cancer patients rent procedures. (lu.se)
Survival from breast cancer has improved during the past dec- markerserumlevelshavebeenusedpreviously,e.g.,incalculating ades in the Western world. (lu.se)

The aim of present study is to assess the involvement of PTPRK in the disease progression of pancreatic cancer. (cardiff.ac.uk)
Pancreatic cancer patients with a higher PTPRK level had poor overall and relapse free survival compared with patients with tumours of low PTPRK expression. (cardiff.ac.uk)
Pancreatic cancer (PC) is a devastating disease. (bmj.com)

In metastatic disease, this palliative therapy has yielded a median progression-free survival of 18-20 months and an overall survival of 24-36 months. (medscape.com)

During radiation, weekly assessments of toxicity were obtained, and for patients with ≥ 90 days of follow-up, late toxicity was assessed. (allenpress.com)
Patients were treated with toripalimab until disease progression or unacceptable toxicity. (medscape.com)
The recommended toripalimab dose with cisplatin and gemcitabine is 240 mg every 3 weeks until disease progression or unacceptable toxicity for up to 24 months. (medscape.com)
The recommended dose of T-DXd is 5.4 mg/kg via intravenous infusion once every 3 weeks until disease progression or unacceptable toxicity. (ascopost.com)
T-DXd has boxed warnings for interstitial lung disease and embryofetal toxicity. (ascopost.com)

Mortality is attributable largely to metastatic disease and a dearth of effective therapeutic interventions. (biologists.com)
To elucidate the biological mechanisms underlying pulmonary metastasis and identify superior therapeutic strategies, we developed a novel and clinically relevant murine RCC model exhibiting enhanced pulmonary metastasis. (biologists.com)
In this setting, the unmet need is high, and new therapeutic approaches are necessary to delay disease progression and extend survival," said Cristian Massacesi, MD, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca. (biospace.com)
Novel therapeutic options, based on an improved understanding of underlying biology and response to therapy, are urgently needed for patients presenting with advanced biliary tract cancer (ABC). (nature.com)

The pivotal Phase 3 study enrolled over 500 patients and demonstrated an improvement in progression free survival (PFS) for patients treated with YONDELIS. (prnewswire.com)
For example, Alecensa showed promise in combination with the antibody drug bevacizumab in a phase 2 trial in patients with advanced ALK-positive NSCLC. (outsourcing-pharma.com)
Although AXLerate-OC did not meet the primary endpoint, I look forward to working with Aravive to analyze the Phase 3 data and determine the most appropriate path to bring batiraxcept to those patients who may benefit most," said Dr. Katherine Fuh, Associate Professor, UCSF Division of Gynecologic Oncology. (aravive.com)
We conducted a pilot randomized phase I trial in PC patients to determine the peptide dose required to induce an optimal CD8 + T cell response. (bmj.com)

After a median follow-up of 25.2 months, the 18-month survival rate was 77 percent for the immunotherapy combination arm compared with 60 percent for the sunitinib arm. (aacr.org)

this is an important endpoint for these patients, in whom rapid worsening of the disease can lead to worse symptoms and life-threatening situations. (prnewswire.com)
Results Sixty-six patients were screened and 19 enrolled of whom 14 received at least 3 doses of the vaccine and thus evaluated for the primary immunologic endpoint. (bmj.com)

The trial enrolled a heterogeneous patient population regarding risk of recurrence, including patients with high-grade pT2 disease to those with metastatic disease who had undergone complete definitive resection of all metastatic disease and were without evidence of metastatic disease on radiographic imaging. (ascopost.com)
before resection of the primary tumor and then postoperatively every 6-12 mo, resulting in three to five samples per patient. (lu.se)

In 2020, the United States Preventive Services Task Force and Centers for Disease Control and Prevention recommended that all pregnant persons be screened during each pregnancy for hepatitis C. However, there are limited data on trends in hepatitis C testing during pregnancy. (cdc.gov)
Centers for Disease Control and Prevention. (cdc.gov)

The study concluded that sCD40L is a valuable diagnostic tool in early diagnosis and screening for HCV and HCC as well as routine follow up of HCV cirrhosis patients. (who.int)

More patients in the panitumumab arm reported skin toxicities, fatigue, abdominal pain, nausea and diarrhea. (amgen.com)
In addition, Enhertu is also associated with significant toxicities, including interstitial lung disease (ILD). (stopbreastcancer.org)

[3],[4] LPS is comprised of several subtypes and develops in fat cells that become cancerous in any part of the body. (prnewswire.com)

Currently the global metastatic cancer therapy market is well flourished with more than 10 unique products including advance cancer therapies like targeted therapy, cancer vaccines, immunotherapies and some modern versions of chemotherapies like Jevtana. (medgadget.com)
On the other hand, highly populated regions like China and India have an opportunistic market for metastatic cancer therapies as the early stage cancer diagnostic market has recently emerged, thus there is a presence of large population living with later stages of cancer. (medgadget.com)
We're committed to developing therapies which have the potential to make a meaningful difference to the lives of people living with cancer and look forward to working with FDA as they review this application. (curetoday.com)
Dr. Rebecca Previs shares data on some exiting emerging therapies in the front line setting for patients with advanced ovarian cancer. (cancernetwork.com)

Moreover, India is already developing vaccines and immunotherapies for metastatic cancer to decrease the mortality rates in the country which will further boost the market by products. (medgadget.com)
Patients treated with palliative-intent SBRT were spared morbidity and mortality from progression of treated lesions, though all developed further metastatic progression shortly (median 4 months) after enrollment. (nih.gov)

The use of sentinel lymph node biopsy (SLNB) could be a promising procedure to assess this risk in clinically N0 patients. (hindawi.com)

Accordingly, extensive efforts have been and continue to be made to develop alternate radiographic criteria to measure efficacy of CIT. (medscape.com)

Adverse reactions in 20% or more of patient with toripalimab monotherapy include fatigue, hypothyroidism, and musculoskeletal pain. (medscape.com)

We report intracellular accumulation of a secreted antigen-targeted antibody (SATA) that can be used to characterize disease, guide therapy, and monitor response. (lu.se)
Fluorescent and radio conjugates of 11B6, an antibody targeting free hK2, are internalized and noninvasively report AR pathway activity in metastatic and genetically. (lu.se)

In terminally ill patients with an anticipated poor outcome, family counseling is crucial for guarding against unreasonable expectations. (medscape.com)
Family counseling for a terminally ill patient with an anticipated poor outcome is crucial to avoid any unreasonable expectations from arising. (medscape.com)
However, the use of death as a study outcome and the fact that these studies were performed with patients with different sources of bacteremia make it difficult to interpret study results. (cdc.gov)

or =5 metastatic lesions, were treated with palliative-intent. (nih.gov)
These patterns include an initial transient increase in tumor burden before response [ 4 , 5 ] and/or appearance of new lesions (NLs) in patients with responding baseline lesions. (medscape.com)

A total of 103 patients (68 percent) did not have a PCND, and only two patients in this cohort developed a central neck recurrence by final follow-up. (mskcc.org)
A total of 221 children (Cohort-1) were included, of which 182 patients had non-metastatic disease (Cohort-2). (ecancer.org)
FOXO1-fusion status was available in 140 patients with localised RMS (Cohort 3). (ecancer.org)
OBJECTIVE: We estimated hepatitis C testing rates in a large cohort of patients with Medicaid and commercial insurance who gave birth during 2015-2019 and described demographic and risk-based factors associated with testing. (cdc.gov)
A 21- ticular valuable source, because it is useful not only for the initial protein signature was identified, using leave-one-out cross-validation screening of the disease but also for continuous monitoring of the together with a backward elimination strategy in a training cohort. (lu.se)

This risk assessment was not dependent on the type of adju- decoding patterns of immunoregulatory serum proteins could re- vant therapy received by the patients. (lu.se)
Serum sCD40Lshowed statistically-significant high levels in HCV-HCC patients compared to HCV-cirrhotic patients and normal controls (P (who.int)
Serum sCD40L had higher diagnostic value in HCC patients compared with serum AFP. (who.int)
Assessment of serum IL-10 levels in HCV patients may provide a possible predictive marker for disease progression. (who.int)

In patients with anti-panitumumab antibodies, there was no impact on efficacy, safety and pharmacokinetics. (amgen.com)
In addition, according to the FDA statement, the combination did not show efficacy for patients with favorable-risk disease. (aacr.org)

In this context, the role of SLNB in nonmelanoma skin cancer should be accepted as a standard staging procedure assuming that N status is a strong predictive factor for survival. (hindawi.com)
MICs for vancomycin and daptomycin were higher in these patients (optimal cutoff values for predictive accuracy = 1.5 μg/mL and 0.5 μg/mL). (cdc.gov)

Anatomy6

Organisms6

Diseases88

Chemicals and Drugs50

Analytical, Diagnostic and Therapeutic Techniques and Equipment90

Phenomena and Processes15

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena1

Information Science7

Health Care33

Geographicals1

Chemotherapy30

Renal cell carc16

Colorectal8

Prognosis10

Melanoma21

Tumors10

Unresectable or metastatic1

Clinical31

Women with metastatic disease1

Prognostic9

Median overall6

Recurrent6

Outcomes8

Adjuvant6

Prostate29

Previously treated4

Distant metastatic1

Metastases10

Mutations12

Incidence1

HER27

Surgical Resection2

Cancers8

Metastasis-free survival3

Treatment34

Tumor types2

Carcinoma2

Versus12

Breast cancer13

Pancreatic3

Yielded a median1

Toxicity5

Therapeutic4

Phase4

Immunotherapy1

Endpoint2

Resection2

Centers for Diseas2

Diagnosis1

Toxicities2

Subtypes1

Therapies4

Mortality2

Clinically1

Radiographic1

Monotherapy1

Antibody2

Outcome3

Lesions2

Cohort5

Serum4

Efficacy2

Predictive2